Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration with Novartis to discover and develop in ...

The Northwell Health Cancer Institute is the Most Recent Clinical Site to Join the TIGeR-PaC Study, and RenovoRx Aims to Reach Full Patient Enrollment in the First Half of 2025 Phase III Clinical ...

Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in ...

The results were so strong in showing the benefit of this therapy for patient survival that we were able to stop the trial ...

A new type of therapy that ‘edits’ a gene in patients with a rare heart condition has been shown to be safe and effective, ...

Boost your inner glow and optimize your output with these IV drips to prep you pre-summer and post-summer shine.

EPI-003 is set to become the world's first epigenetic therapy to reach clinical trials for this widespread infectious disease. EPI-003 is a breakthrough antiviral drug administered through intravenous ...

Kelly's acquisition of Children's Therapy Center (CTC) further expands growth opportunities in the high-margin, high-demand therapeutic services ...

A new type of therapy that "edits" a gene in patients with a rare heart condition has been shown to be safe and effective, ...

Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...